Sun Xiaodong, Qiu Wei, Chen Yuguo, Lv Guoyue, Fan Zhongqi
Department of Hepatobiliary & Pancreas Surgery, The First Hospital, Jilin University, Changchun, Jilin, China.
Medicine (Baltimore). 2018 Sep;97(37):e12407. doi: 10.1097/MD.0000000000012407.
Severe cardiac dysfunction or severe pulmonary hypertension is a contraindication of liver transplantation (LT). Extracorporeal membrane oxygenation (ECMO) is an advanced therapy for severe lung and/or cardiocirculatory dysfunction or failure. The application of ECMO to patients during the LT perioperative period may help recipients with severe cardiac disease to maintain the heart function and alleviate the reperfusion syndrome.
A female liver recipient complained about weakness for 6 months.
The patient was diagnosed as hepatitis B virus (HBV)-related hepatic cirrhosis (MELD 24, Child-Pugh C) with severe mitral regurgitation, severe tricuspid regurgitation, left atrium and left ventricle enlargement, cardiac insufficiency, pulmonary arterial hypertension, and hypoxemia.
The patient underwent LT from a cardiac deceased donor. The surgery was completed by venoarterial ECMO. The femoral vessels cannulation was done after the dissection of the patient's liver and before the venous blocking. Venous cannula reached to the position below renal vein, while arterial cannula reached to common iliac artery. We regulated the ECMO index according to the patient's condition. The dosage of heparin was adjusted on the basis of the activated clotting time. Respiratory support, milrinone, furosemide, and mannitol were used to improve the circulation. The bleeding volume of surgery was 1200 mL. The cardiocirculatory function and other vital signs remained good in the perioperative period. In the first 24 hours after surgery, central venous pressure decreased from 17 to 7 cmH2O. Thirty hours after surgery, the ECMO was removed. Eighteen hours later, the recipient did not need respiratory support.
No complications of transplantation or ECMO were found.
It is feasible to utilize ECMO as a cardiocirculatory function support in the LT. ECMO does not increase the risk of hemorrhage. ECMO can play an important role in ensuring the security of the liver recipients in the surgery and in the postoperative period.
严重的心功能不全或严重的肺动脉高压是肝移植(LT)的禁忌症。体外膜肺氧合(ECMO)是治疗严重肺和/或心肺循环功能障碍或衰竭的一种先进疗法。在LT围手术期将ECMO应用于患者可能有助于患有严重心脏疾病的受者维持心脏功能并减轻再灌注综合征。
一名女性肝移植受者主诉乏力6个月。
该患者被诊断为乙型肝炎病毒(HBV)相关肝硬化(终末期肝病模型评分24分,Child-Pugh C级),伴有严重二尖瓣反流、严重三尖瓣反流、左心房和左心室扩大、心功能不全肺动脉高压和低氧血症。
该患者接受了来自心脏死亡供体的肝移植。手术通过静脉-动脉ECMO完成。在解剖患者肝脏后且在静脉阻断前进行股血管插管。静脉插管到达肾静脉下方位置,而动脉插管到达髂总动脉。我们根据患者情况调整ECMO参数。根据活化凝血时间调整肝素剂量。使用呼吸支持、米力农、呋塞米和甘露醇改善循环。手术出血量为1200毫升。围手术期心肺循环功能和其他生命体征保持良好。术后24小时内,中心静脉压从17厘米水柱降至7厘米水柱。术后30小时,撤除ECMO。18小时后,受者不再需要呼吸支持。
未发现移植或ECMO相关并发症。
在肝移植中利用ECMO作为心肺循环功能支持是可行的。ECMO不会增加出血风险。ECMO在确保肝移植受者手术及术后安全方面可发挥重要作用。